Results 221 to 230 of about 106,533 (346)

Impact of Anti‐obesity Medication Initiation and Duration on Weight Loss

Obesity Science &Practice, Volume 11, Issue 2, April 2025.
This retrospective study of 1282 patients found that long‐term AOM usage contributed to significant weight loss (14.70%–17.34%) compared to short term AOM use (9.25%–12.56%). The study observes that non‐AOM users within a structured obesity care program can also achieve notable weight loss (9.99%–12.77%), highlighting the potential effectiveness of ...
M. Rami Bailony, Paulina Garzon Espinoza, Harun Yüksel, Imran M. Kyeso, Roxana Khalili, Sheryl Haller   +5 more
wiley   +1 more source

Probing structure and function of VLDL by synthetic amphipathic helical peptides

Journal of Lipid Research, 1996
Class A amphipathic helical peptides have been shown to mimic many properties of exchangeable apolipoproteins. The three analogs of the class A amphipathic peptides were used to probe the structure and function of human very low density lipoproteins ...
B H Chung, M N Palgunachari, V K Mishra, C H Chang, J P Segrest, G M Anantharamaiah   +5 more
doaj  

Phenotypic upregulation of hexocylceramides and ether‐linked phosphocholines as markers of human extreme longevity

Aging Cell, Volume 24, Issue 4, April 2025.
Mass spectrometry analysis of 569 lipid species showed that ceramide‐to‐hexosylceramide conversion and the preservation of ether‐linked PC levels are key phenotypic traits ensuring extreme longevity. This lipidomic signature is shaped by an intrinsic adaptive program that maintains protective mechanisms and cellular identity.
Anna Fernàndez‐Bernal, Joaquim Sol, José Daniel Galo‐Licona, Natàlia Mota‐Martorell, Cristina Mas‐Bargues, Ángel Belenguer‐Varea, Èlia Obis, José Viña, Consuelo Borrás, Mariona Jové, Reinald Pamplona   +10 more
wiley   +1 more source

Direct Binding of Reelin to VLDL Receptor and ApoE Receptor 2 Induces Tyrosine Phosphorylation of Disabled-1 and Modulates Tau Phosphorylation

Neuron, 1999
T. Hiesberger, M. Trommsdorff, B. Howell, A. Goffinet, M. Mumby, Jonathan A. Cooper, J. Herz   +6 more
semanticscholar   +1 more source

Reduced insulin-mediated inhibition of VLDL secretion upon pharmacological activation of the liver X receptor in mice

Journal of Lipid Research, 2009
The nuclear liver X receptor (LXR) regulates multiple aspects of cholesterol, triacylglycerol (TG), and carbohydrate metabolism. Activation of LXR induces the expression of genes encoding enzymes involved in de novo lipogenesis (DNL) resulting in hepatic
Aldo Grefhorst, Elizabeth J. Parks
doaj  

The Lipidomic Profile Discriminates Between MASLD and MetALD

Alimentary Pharmacology &Therapeutics, Volume 61, Issue 8, Page 1357-1371, April 2025.
HDL‐centric lipidomic biomarkers, particularly within large and medium HDL subfractions, distinguish metabolic dysfunction and alcohol‐related liver disease from metabolic dysfunction‐associated steatotic liver disease, suggesting potential biomarkers for clinical differentiation.
Kai Markus Schneider, Feng Cao, Helen Ye Rim Huang, Lanlan Chen, Yazhou Chen, Rongpeng Gong, Anastasia Raptis, Kate Townsend Creasy, Jan Clusmann, Felix van Haag, Paul‐Henry Koop, Adrien Guillot, Tom Luedde, Rohit Loomba, Sven Francque, Carolin Victoria Schneider   +15 more
wiley   +1 more source

Establishing the Role of Liver Fatty Acid-Binding Protein in Post-Golgi Very-Low-Density Lipoprotein Trafficking Using a Novel Fluorescence-Based Assay. [PDF]

Int J Mol Sci
Winterfeldt K, Tasin FR, Siddiqi SA.
europepmc   +1 more source

Hypertriglyceridemic VLDL Downregulates Tissue Plasminogen Activator Gene Transcription Through cis -Repressive Region(s) in the Tissue Plasminogen Activator Promoter in Cultured Human Endothelial Cells [PDF]

, 2000
Edlue M. Tabengwa, Raymond L. Benza, Hernan E. Grenett, François M. Booyse   +3 more
openalex   +1 more source

Novel drugs approved by the EMA, the FDA and the MHRA in 2024: A year in review

British Journal of Pharmacology, Volume 182, Issue 7, Page 1416-1445, April 2025.
Abstract In the past year, the European Medicines Agency (EMA), the Food and Drug Administration (FDA) and the Medicines and Healthcare Products Regulatory Agency (MHRA) authorised 53 novel drugs. While the 2024 harvest is not as rich as in 2023, when 70 new chemical entities were approved, the number of ‘orphan’ drug authorisations in 2024 (21) is ...
Stavros Topouzis, Andreas Papapetropoulos, Steve P. H. Alexander, Miriam Cortese‐Krott, Dave A. Kendall, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Mauro M. Teixeira, Nathalie Vergnolle, Xin Wang, Péter Ferdinandy   +16 more
wiley   +1 more source

The causal impact of body mass index on metabolic biomarkers and nonalcoholic fatty liver disease risk. [PDF]

Sci Rep
Wang B, Yang Y, Yin Z, Yang W.
europepmc   +1 more source